CANNAPHARMARX Business Summary

CANNAPHARMARX, INC. (CPMD) operates as a specialized cannabis company focused on the acquisition, development, and operation of high-efficiency cultivation facilities, primarily through its flagship 40,000-square-foot facility in Cremona, Alberta. The company generates revenue through transaction-based sales of medical-grade dried cannabis flower, trim, and shake, targeting high-demand international markets including Germany and Israel. Its business segments are centered on the production of craft cannabis and unique genetic strains, with a strategic pivot toward global export to capitalize on higher price points for premium, high-THC products. Within the competitive landscape, CPMD contends with established players such as Cronos Group Inc., Akanda Corp, and Lyra Therapeutics; it currently occupies a niche as an emerging micro-cap exporter, leveraging EU-GMP compliant standards to differentiate its supply chain for European pharmaceutical distribution. The leadership team is currently headed by Constantine Nkafu, who serves as Interim CEO and Director, bringing over two decades of experience across the pharmaceutical, medical device, and cannabis sectors. He is supported by CFO Oliver Foeste, a CPA and Managing Partner of Invictus Accounting Group with extensive expertise in financial advisory for natural resources and technology firms. The Board of Directors is chaired by Rick Orman and includes former CEO Dominick Colvin, along with independent directors Anthony Panek and Elliot Zemel, the latter of whom provides a background in healthcare and e-commerce management. A notable institutional influence is LTB Management, LLC, which holds significant Series C Preferred Shares and maintains the right to appoint board members, reflecting a concentrated investor interest in the company’s 2026 expansion strategy.